Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoD
danny2024-01-31T15:12:09-05:00Award will advance the Self-Assembling Vaccine Platform for rapid [...]
Lucius Partners Portfolio Company Voltron Therapeutics, Inc Adds Manufacturing Expert to Scientific Advisory Board
danny2024-01-31T15:09:40-05:00Globally recognized manufacturing and product supply expert Tibor [...]
Lucius Partners Portfolio Company Voltron Therapeutics Announces Robust Immunogenicity Data: Key Prostate Cancer Target
danny2023-09-06T15:53:23-04:00Self Assembling Vaccine targets Prostate Stem Cell Antigen [...]
Voltron Therapeutics, a Lucius Partners Company, with the VIC at MGH Announces $5.88 Million Award from U.S. DoD
danny2023-08-25T14:19:08-04:00Voltron Therapeutics, a Lucius Partners Company, with the [...]
Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Sponsored Research Agreement with the Massachusetts General Hospital, Harvard Medical School, to Initiate a Pre-clinical Immuno-Oncology Trial
Monalisa Moody2023-08-25T14:20:35-04:00Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces [...]
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Poster Presentation at the Military Health System Research Symposium
Monalisa Moody2023-04-05T19:21:55-04:00Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Definitive Proof of Concept Data for its Lead Oncology Candidate (VTX-067) in an HPV Related Tumor Challenge Study
Monalisa Moody2023-04-05T20:03:51-04:00Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]
Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Industry Veteran Dr. Tony Hodges has Joined the Company as Senior Scientific Advisor
Monalisa Moody2023-04-05T18:58:29-04:00Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, [...]
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology
Monalisa Moody2023-04-05T13:22:39-04:00Voltron Therapeutics, Inc., a Lucius Partners Company, Announces [...]
Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio Company, Announces Industry Veteran Dr. Simon Pedder has Joined the Board of Directors
Monalisa Moody2023-04-05T18:47:16-04:00Voltron Therapeutics, Inc., a Laidlaw Venture Partners Portfolio [...]